Abstract: The present invention relates to the field of medicine and provides pharmaceutical compositions comprising one or more of the following isolated amino acid sequences comprising or, alternatively, consisting of, SEQ ID No.: 3, and/or SEQ ID No.: 1, and/or SEQ ID No.: 2, kits and conjugates comprising one or more of the above mentioned amino acid sequences. In addition, the present invention relates to the use of the pharmaceutical compositions, kits and conjugates of the present invention as a medicament, in particular in the treatment of an infectious disease, or of an inflammatory condition related to an infectious disease, or of an inflammatory disease related to the presence of a product derived from an infectious agent. The present invention also provides a device for selective binding and separation of at least one component from an aqueous solution wherein the device comprises one or more of the above mentioned amino acid sequences.

Abstract: The present invention relates to the field of medicine and provides pharmaceutical compositions comprising one or more of the following isolated amino acid sequences comprising or, alternatively, consisting of, SEQ. ID No.: 3, and/or SEQ. ID No.: 1, and/or SEQ ID No.: 2, kits and conjugates comprising one or more of the above mentioned amino acid sequences. In addition, the present invention relates to the use of the pharmaceutical compositions, kits and conjugates of the present invention as a medicament, in particular in the treatment of an infectious disease, or of an inflammatory condition related to an infectious disease, or of an inflammatory disease related to the presence of a product derived from an infectious agent. The present invention also provides a device for selective binding and separation of at least one component from an aqueous solution wherein the device comprises one or more of the above mentioned amino acid sequences.

Abstract: The present invention relates to the field of medicine and provides compositions and kits-of-parts comprising a CD6 product and Imipenem, in particular for their use in a therapeutic and/or preventive method of treatment, in a mammal including a human, of an infectious disease, or of an inflammatory condition related to an infectious disease, or of an inflammatory disease related to the presence of a product derived from an infectious agent.

Abstract: The present invention relates to the field of medicine and provides pharmaceutical compositions comprising one or more of the following isolated amino acid sequences comprising or, alternatively, consisting of, SEQ. ID No.: 3, and/or SEQ. ID No.: 1, and/or SEQ ID No.: 2, kits and conjugates comprising one or more of the above mentioned amino acid sequences. In addition, the present invention relates to the use of the pharmaceutical compositions, kits and conjugates of the present invention as a medicament, in particular in the treatment of an infectious disease, or of an inflammatory condition related to an infectious disease, or of an inflammatory disease related to the presence of a product derived from an infectious agent. The present invention also provides a device for selective binding and separation of at least one component from an aqueous solution wherein the device comprises one or more of the above mentioned amino acid sequences.

Abstract: The present invention relates to the field of medicine and provides compositions and kits-of-parts comprising a CD6 product and Imipenem, in particular for their use in a therapeutic and/or preventive method of treatment, in a mammal including a human, of an infectious disease, or of an inflammatory condition related to an infectious disease, or of an inflammatory disease related to the presence of a product derived from an infectious agent.

Abstract: The present invention discloses soluble isoforms of CD5 and CD6, which are scavenger-like lymphocyte receptors, for use in the prophylaxis or therapy of disorders or in therapeutic interventions, which would benefit from an exacerbated immune response to either endogenous or exogenous antigens, resulting from a decrease in lymphocyte subpopulations with regulatory functions and/or increase in lymphocyte subpopulations with effector functions. Special disorders are cell growth disorders, and chronic infections of bacterial, viral, fungal or parasitic origin. The invention also provides animal models for the study and the prophylaxis/treatment of autoimmune diseases, cancer, and chronic infections.

Abstract: The present invention discloses soluble isoforms of CD5 and CD6, which are scavenger-like lymphocyte receptors, for use in the prophylaxis or therapy of disorders or in therapeutic interventions, which would benefit from an exacerbated immune response to either endogenous or exogenous antigens, resulting from a decrease in lymphocyte subpopulations with regulatory functions and/or increase in lymphocyte subpopulations with effector functions. Special disorders are cell growth disorders, and chronic infections of bacterial, viral, fungal or parasitic origin. The invention also provides animal models for the study and the prophylaxis/treatment of autoimmune diseases, cancer, and chronic infections.

Abstract: The inventors have found that CD6, a member of the Scavenger Receptor Cysteine-Rich (SRSR) superfamily expressed on human lymphocytes binds to Gram-positive and Gram-negative bacteria, as well as to other microbial structures. Thus, a CD6 product is useful for the manufacture of a medicament for therapeutic and/or preventive treatment of an infectious disease or of an inflammatory condition related to an infectious disease or to the presence of a product derived from an infectious agent in a mammal including a human. Examples of such inflammatory conditions are systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis and septic shock.

Abstract: The present invention refers to pharmaceutical compositions comprising the soluble CD5 ectodomain and its use for the prevention and/or treatment of fungal infections and/or fungal sepsis, as well as inflammatory disorders of fungal origin.

Abstract: The present invention refers to pharmaceutical compositions comprising the soluble CD5 ectodomain and its use for the prevention and/or treatment of fungal infections and/or fungal sepsis, as well as inflammatory disorders of fungal origin.

Abstract: The inventors have found that CD6, a member of the Scavenger Receptor Cysteine-Rich (SRSR) superfamily expressed on human lymphocytes binds to Gram-positive and Gram-negative bacteria, as well as to other microbial structures. Thus, a CD6 product is useful for the manufacture of a medicament for therapeutic and/or preventive treatment of an infectious disease or of an inflammatory condition related to an infectious disease or to the presence of a product derived from an infectious agent in a mammal including a human. Examples of such inflammatory conditions are systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis and septic shock.